Cargando…

Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model

Pancreatic cancer is a highly lethal disease in part due to incomplete tumor resection. Targeting by tumor-specific antibodies conjugated with a fluorescent label can result in selective labeling of cancer in vivo for surgical navigation. In the present study, we describe a patient-derived orthotopi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lwin, Thinzar M., Miyake, Kentaro, Murakami, Takashi, DeLong, Jonathan C., Amirfakhri, Siamak, Filemoni, Filemoni, Yoon, Sang Nam, Yazaki, Paul J., Shivley, John E., Datnow, Brian, Clary, Bryan M., Hoffman, Robert M., Bouvet, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324662/
https://www.ncbi.nlm.nih.gov/pubmed/30647873
http://dx.doi.org/10.18632/oncotarget.26484
Descripción
Sumario:Pancreatic cancer is a highly lethal disease in part due to incomplete tumor resection. Targeting by tumor-specific antibodies conjugated with a fluorescent label can result in selective labeling of cancer in vivo for surgical navigation. In the present study, we describe a patient-derived orthotopic xenograft model of pancreatic cancer that recapitulated the disease on a gross and microscopic level, along with physiologic clinical manifestations. We additionally show that the use of an anti-CEA antibody conjugated to the near-infrared (NIR) fluorescent dye, IRDye800CW, can selectively highlight the pancreatic cancer and its metastases in this model with a tumor-to-background ratio of 3.5 (SEM 0.9). The present results demonstrate the clinical potential of this labeling technique for fluorescence-guided surgery of pancreatic cancer.